This may be due to the fact that taltobulin has a low affinity for ABC transporters (35), a promising feature that has led to the use of taltobulin in clinical trials for the treatment of non-small-cell lung cancer (36). Here, ABCG2 is linked to non-small cell lung carcinoma.